

해외 바이오의약품 임상 현황 (2019.10.22~2019.10.28)

한국바이오의약품협회, 2019.10.29
출처: ClinicalTrials.gov

○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03579927	CAR,CD19-CD28-zeta-2a-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	CD19 Positive Mantle Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma	Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Carmustine Drug: Cytarabine Drug: Etoposide Biological: Filgrastim Drug: Melphalan Biological: Rituximab Biological: Umbilical Cord Blood-derived Natural Killer Cells	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04080804	Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer	Head and Neck Squamous Cell Carcinoma (HNSCC)	Drug: Nivolumab Drug: Relatlimab Drug: Ipilimumab	Robert Ferris Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04019041	A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa	Hidradenitis Suppurativa Acne Inversa Suppurative Hidradenitis	Drug: bermekimab Drug: placebo	XBioTech, Inc.	Phase 2
NCT03388008	Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation	Lung Transplant Rejection Antibody-mediated Rejection	Drug: Belatacept Drug: Tacrolimus Drug: ATG Drug: Mycophenolate Mofetil Drug: Methylprednisolone Drug: Prednisone	Washington University School of Medicine National Heart, Lung, and Blood Institute (NHLBI) Bristol-Myers Squibb	Phase 2
NCT04133636	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528	Janssen Research & Development, LLC	Phase 2
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3

○ 영국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04086472	Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of MK-1654 in Healthy Participants (MK-1654-005)	Respiratory Syncytial Viruses	Biological: MK-1654 Other: Placebo Biological: RSV-A Memphis 37b	Merck Sharp & Dohme Corp.	Phase 2
NCT03371862	Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)	Short Bowel Syndrome	Drug: Liraglutide Pen Injector [Victoza]	Imperial College London	Phase 2
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3

○ 프랑스 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03968419	This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.	Non-small Cell Lung Cancer	Drug: canakinumab Drug: pembrolizumab	Novartis Pharmaceuticals Novartis	Phase 2
NCT04132960	Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis	Breast Tumors	Drug: DS-8201a	UNICANCER Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Phase 2
NCT04006262	Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma	Localized Oesogastric Adenocarcinoma MSI and/or dMMR	Drug: Nivolumab 10 MG/ML Drug: Ipilimumab 200 MG in 40 ML Injection	GERCOR - Multidisciplinary Oncology Cooperative Group Bristol-Myers Squibb	Phase 2
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3
NCT04133636	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528	Janssen Research & Development, LLC	Phase 2

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	Melanoma	Biological: Nivolumab Other: Placebo	Bristol-Myers Squibb	Phase 3
NCT04133636	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528	Janssen Research & Development, LLC	Phase 2

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04091217	Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma	Melanoma	Drug: Atezolizumab Drug: Bevacizumab	Hoffmann-La Roche	Phase 2